Related Experiment Video
Updated: May 9, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
Published on: November 10, 2017
The beneficial effects of statins in patients undergoing hemodialysis
Chin-Chou Huang1, Wan-Leong Chan, Yu-Chun Chen
1Department of Medical Research and Education, Taipei Veterans General Hospital, Taipei, Taiwan, R.O.C.; Division of Cardiology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan, R.O.C.; Cardiovascular Research Center, National Yang-Ming University, Taipei, Taiwan, R.O.C.; Institute of Pharmacology, National Yang-Ming University, Taipei, Taiwan, R.O.C.
Insights
Statin use significantly reduced cardiovascular events and mortality in hemodialysis patients. This study demonstrates statins
Area of Science:
- Nephrology
- Cardiology
- Pharmacology
Background:
- The efficacy of statin therapy in patients undergoing hemodialysis remains a subject of debate.
- Cardiovascular disease is a leading cause of mortality in patients with end-stage renal disease requiring hemodialysis.
Purpose of the Study:
- To evaluate the association between statin use and the risk of cardiovascular morbidity and mortality in hemodialysis patients.
Main Methods:
- A cohort study utilized data from the Taiwan National Health Insurance Research Database.
- Cox regression analysis was employed to compare outcomes between statin users and propensity-matched non-users undergoing hemodialysis.
Main Results:
- The statin cohort (4074 patients) exhibited significantly lower incidences of ischemic stroke, unstable angina, deep vein thrombosis, cardiovascular mortality, and all-cause mortality compared to the non-statin cohort (8148 patients).
- Statin use was independently associated with reduced risks for ischemic stroke (HR, 0.49), unstable angina hospitalization (HR, 0.57), deep vein thrombosis (HR, 0.11), cardiovascular mortality (HR, 0.29), and all-cause mortality (HR, 0.49).
Conclusions:
- Statin therapy is associated with a significant reduction in cardiovascular morbidity and mortality among patients undergoing hemodialysis.
- These findings support the consideration of statin use in hemodialysis patients to mitigate cardiovascular risks.
Background:
The beneficial effects of statins in patients undergoing hemodialysis are controversial. Our study aimed to investigate the use of statins and the subsequent risk of cardiovascular morbidity and mortality in patients undergoing hemodialysis.
Methods:
We conducted a cohort study using data from the Taiwan National Health Insurance Research Database. Cox regressions were performed to determine the hazard ratio (HR) of cardiovascular morbidity and mortality in the HD patients taking statins (statin cohort) compared with a propensity-matched comparison cohort.
Results:
The statin cohort included a total of 4074 patients who received statin treatment while also undergoing hemodialysis (mean age 53.3 ± 13.5 years, male 34.9%). The comparison cohort included 8148 propensity-matched hemodialysis patients who were not using statins. During the three years of follow-up, the statin cohort had lower incidence of ischemic stroke (p < 0.001), hospitalizations due to unstable angina (p < 0.001), deep vein thrombosis (p < 0.001), cardiovascular mortality (p < 0.001), and all-cause mortality (p < 0.001). After Cox regression analysis, statin use was independently associated with lower risk of future ischemic stroke (HR, 0.49; 95% confidence interval [CI], 0.39-0.63), hospitalization for unstable angina (HR, 0.57; 95% CI, 0.47-0.70), deep vein thrombosis (HR, 0.11; 95% CI, 0.05-0.27), cardiovascular mortality (HR, 0.29; 95% CI, 0.18-0.46), and all-cause mortality (HR, 0.49; 95% CI, 0.41-0.58).
Conclusion:
Statin use was associated with a lower incidence of cardiovascular morbidity and mortality in patients undergoing hemodialysis.
Related Concept Videos
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Hemodialysis II: Procedure and Complications
Hemodialysis I: Introduction
Hemodialysis III: Nursing Management
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Acute Kidney Injury IV: Diagnostic Studies and Prevention